Novonesis A/S (NSIS-B.CO)
| Previous Close | 414.40 |
| Open | 415.00 |
| Bid | 409.50 x N/A |
| Ask | 409.60 x N/A |
| Day's Range | 407.40 - 417.80 |
| 52 Week Range | 343.90 - 485.90 |
| Volume | |
| Avg. Volume | 593,932 |
| Market Cap | 190.34B |
| Beta (5Y Monthly) | 0.54 |
| PE Ratio (TTM) | 58.89 |
| EPS (TTM) | 6.96 |
| Earnings Date | Feb 26, 2025 |
| Forward Dividend & Yield | 8.20 (1.98%) |
| Ex-Dividend Date | Aug 29, 2024 |
| 1y Target Est | 484.06 |
GlobeNewswireQ3 update: Novonesis delivers strong Q3 results and now expects full-year organic sales growth at the upper end of 7-8%
Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong performance has led Novonesis to now expect full-year organic sales growth to be at the upper end of the 7-8% range, and the adjusted EBITDA margin is confirmed to be between 35.5-36.5%. COPENHAGEN, Denmark – November 7, 2024. Novonesis delivers 9% organic sales growth, in the first nine months of the 2
- GlobeNewswire
Trading statement 9M 2024
Organic pro forma sales growth of 9%, including 11% in the third quarter. Full-year organic sales growth outlook now expected at the upper end of the 7-8% range and the adjusted EBITDA margin confirmed between 35.5-36.5%. Ester Baiget, President & CEO: “We continue to execute strongly across the business. Supportive, broad-based demand coupled with strong innovation and commercial focus drive higher market penetration. Novonesis’ biosolutions are increasingly requested by customers to make their
